Before the pandemic, telemedicine accounted for less than 1% of all clinician visits, but that number spiked to over 50% following the appearance of COVID-19 cases in the United States. Although telemedicine encounters have since decreased, they remain steady at approximately 15% of clinician visits. Telemedicine is here to stay, and laboratories need to consider the potential impact of this shift in care delivery on their business models.
Download our white pape to learn the following three strategies to maintain your competitive advantage in a rapidly changing industry:
Andrew Fletcher, MD, MBA, CPE, CHCQM, FCAP
Dr. Andrew Fletcher is medical director of Consultative Services at ARUP Laboratories and clinical adjunct professor at the University of Utah School of Medicine. He is a board-certified anatomic/clinical pathologist, certified physician executive, and certified in Health Care Quality Management. He earned his medical degree from the Mercer University School of Medicine in Georgia and his MBA from the University of Massachusetts at Amherst. He has significant experience in leading quality initiatives that enhance organizations’ safety and value and has received numerous awards for quality and utilization, including research grants for blood utilization.
Sandy Richman, MBA, C(ASCP)
Sandy Richman is director of Consultative Services at ARUP Laboratories with nearly 20 years of combined clinical, financial, and consulting experience in the healthcare industry. Before joining ARUP, Sandy was vice president of Healthcare Advisory Services at PNC Healthcare, where he worked closely with leadership teams from hospitals across the country to improve their revenue cycle and treasury management operations. He holds an MBA from the University of Utah and is board certified as a technologist in chemistry by the American Society for Clinical Pathology.